| ALTIMMUNE INC. DL-,0001 |
| USA |
| Gesundheit |
| US02155H2004 / A2N5Z6 |
| 3G0 (Frankfurt) / ALT (NASDAQ) |
| FRA:3G0, ETR:3G0, 3G0:GR, NASDAQ:ALT |
| - |
| https://altimmune.com/ |
|
Altimmune, Inc. is a biopharmaceutical company engaged in the development of immunotherapeutics that address significant unmet medical needs. The company's primary focus is on advancing proprietary th..
>Volltext.. |
| 449.32 Mio. EUR |
| 281.88 Mio. EUR |
| 0.02 Mio. EUR |
| -77.92 Mio. EUR |
| -72.37 Mio. EUR |
| -0.92 EUR |
| 13.72 Mio. EUR |
| 52.85 Mio. EUR |
| -57.48 Mio. EUR |
| 16.72 |
| -63.51% |
| 23.09% |
| - |
| - |
| - |
| 20.01.17 - 224502.93€ |
| - |
| ALTIMMUNE |
| 05.03.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|